Please assess the completion status of the following clinical trial:

Trial Title: CuraLin Herbal Supplement for Type 2 Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Community-dwelling adults ≥18 and ≤ 75 years of age.~* Have an existing diagnosis of type 2 diabetes without known complications; i.e. eye damage (retinopathy), nerve damage (diabetic peripheral neuropathy), kidney damage (diabetic kidney disease), or heart damage (recent myocardial infarction or severe congestive heart failure).~* Must be on a stable dose (i.e. consistent dose for three months or greater) of all medications.~* Must be on a stable dose of dietary supplements for one month prior to enrollment.~* Have a serum hemoglobin A1c between 7% and 9.5%.~* Able to communicate via email, fill out a computer-administered questionnaire, and to read and write in English.~* Willing to have blood drawn at 3 separate time points.~* Willing to take an herbal supplement three times a day, daily, for 12 weeks.~* Willing to abstain from new anti-diabetic therapies, vitamins, minerals, dietary supplements, and lipid-lowering agents for 12 weeks.~* Willing and able to follow the study protocol and attend study visits.~* Approved to be eligible for study participation at the discretion of the Principal Investigators, after review of the Formal Eligibility Screen results.~Exclusion Criteria:~* Allergy to any ingredient found in the study product (Mormordica charantia (fruit), Gymnema sylvestre (leaf), Trigonella foenum-Graecum (seed), Curcuma longa (rhizome), Phyllanthus embilica officinalis (fruit), Swertia chiraytia (leaf), Syzgium Cumini (seed), Neopicrorhiza Picrorhiza/Scrophulariiflora Kurroa (root), Cinnamoum verum/zeylanicum, Hydroxypropyl methylcellulose, Rice Flour).~* Current use of insulin.~* Current use of CuraLin or any dietary supplement that has the same ingredients as CuraLin (see list of ingredients above).~* Current use of the following lipid-lowering medications: Ezetimibe (Zetia), Cholestyramine (Prevalite, Questran, Questran Light), Colesevelam (Welchol), or Colestipol (Colestid, Colestid Flavored).~* History of myocardial infarction or stroke within the last 6 months, current coronary artery disease, unstable angina, uncontrolled hypertension (i.e. systolic \> 180 or diastolic \> 110), congestive heart failure, or stated history of coronary bypass surgery or heart stent placement.~* Current active diabetic ulcers or history of diabetic neuropathy.~* Active malignancy, with the exception of basal cell carcinoma, squamous cell carcinoma, and/or carcinoma in situ of the cervix.~* Current diagnosis of Small Intestinal Bacterial Overgrowth (SIBO), Small Intestinal Fungal Overgrowth (SIFO), Inflammatory Bowel Disease (IBD; i.e. Crohn's or Ulcerative Colitis), or other diagnosed pathology of the gastrointestinal tract (excluding Irritable Bowel Syndrome, \[IBS\]).~* Presence of an unstable and/or significant medical disorder that would compromise the participant's safety to take part in the study.~* Planned elective surgery within the next 12 weeks.~* Pregnant, nursing, or planning a pregnancy within the next 12 weeks.~* Women of childbearing age not using standard birth control measures.~* History of liver and/or kidney disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): All participants will be asked to take the dietary herbal supplement CuraLin for the duration of the study. All participants will take 2 capsules orally, three times per day following meals for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval